Vertex Pharmaceuticals Inc（VRTX）财务数据VRTXVertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated (VRTX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is TRIKAFTA, accounting for 74.9% of total sales, equivalent to $2.50B. Other significant revenue streams include ALYFTREK and Other product revenues. Understanding this composition is critical for investors evaluating how VRTX navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Vertex Pharmaceuticals Incorporated maintains a gross margin of 85.33%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 38.05%, while the net margin is 32.99%. These profitability ratios, combined with a Return on Equity (ROE) of 23.54%, provide a clear picture of how effectively VRTX converts its operational activities into shareholder value.

In the context of the broader market, VRTX competes directly with industry leaders such as BMY and PFE. With a market capitalization of $128.19B, it holds a significant position in the sector. When comparing efficiency, VRTX's gross margin of 85.33% stands against BMY's 68.03% and PFE's 67.81%. Such benchmarking helps identify whether Vertex Pharmaceuticals Incorporated is trading at a premium or discount relative to its financial performance.

Vertex Pharmaceuticals has shown consistent revenue growth, with total revenue expected to reach $3.33 billion in Q2 2026, up from $2.77 billion in Q1 2026. The company also reported a net income of $1.1 billion for Q2 2026, reflecting strong profitability.